Rare Skin Rash (SDRIFE) Linked to Tirzepatide Use in Case Report
Background
SDRIFE, or Symmetrical Drug-Related Intertriginous and Flexural Exanthema, is a distinct type of drug eruption characterized by a symmetrical erythematous rash primarily affecting skin folds and flexural areas. Tirzepatide is a novel dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, widely used for the treatment of type 2 diabetes and obesity. While tirzepatide is generally well-tolerated, various adverse events, particularly gastrointestinal, have been reported; however, the occurrence of SDRIFE specifically associated with tirzepatide had not been previously documented.
Study Design
Results
Approximately two weeks after initiating tirzepatide treatment, the patient presented with a symmetrical erythematous rash that prominently affected her intertriginous and flexural areas, including the groin and axillae. The rash was consistent with the clinical presentation of SDRIFE. Upon the discontinuation of tirzepatide, the patient's skin condition showed rapid improvement. The symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) completely resolved within 7 days following the cessation of tirzepatide therapy. This rapid resolution strongly implicated tirzepatide as the causative agent for the observed drug eruption, marking the first reported instance of this specific adverse event with the medication.
Why It Matters
This case report is significant as it highlights a previously unreported dermatological adverse event associated with tirzepatide use. Clinicians prescribing tirzepatide should be aware of SDRIFE as a potential, albeit rare, side effect, particularly given the increasing use of this medication for type 2 diabetes and obesity. Early recognition and prompt discontinuation of tirzepatide are crucial for the rapid resolution of SDRIFE and to prevent unnecessary diagnostic procedures or treatments. This finding contributes valuable information to the growing safety profile of tirzepatide and underscores the importance of pharmacovigilance for new and widely adopted therapies.